The Limited Times

Now you can see non-English news...

Curevac adds: Next vaccine candidate from Germany - it should work better

2021-08-23T13:50:17.730Z


Curevac had suffered a flop with his first vaccine. Now the German company is hoping for success with the successor to the vaccine. The data looks promising.


Curevac had suffered a flop with his first vaccine.

Now the German company is hoping for success with the successor to the vaccine.

The data looks promising.

Tübingen - Most recently, the Curevac company hoped for approval soon with its first-generation CVnCoV vaccine.

Then came the sobering result: only 48 percent effectiveness against the coronavirus could be determined in phase 3 of the investigations.

With that, the vaccine was out and the biopharmaceutical company's stock plummeted.

Curevac is still trying to recover from this setback.

Still, nobody wants to give up and so the employees are researching a second-generation CVnCoV vaccine - this time with optimized mRNA.

The current data is promising and is also causing the share to rise again.

Curevac: vaccine successor as a new beacon of hope

Together with the British company GlaxoSmithKline (GSK), Curevac wants to bring a better vaccine to the market.

As reported by the Deutsche Apotheker Zeitung (DAZ), among others, the study is still in the preclinical phase on non-human primates.

According to this, a comparison is made with cynomolgus monkeys of how they react to the vaccines of the first and second generation.

A period of 28 days was observed for the study.

"It was found that compared to the first-generation vaccine candidate, CVnCoV, CV2CoV activates innate and adaptive immune responses better and thus achieves a faster onset of the immune response, higher antibody titers and greater activation of B and T memory cells," said Curevac.

It also showed good effectiveness against various virus variants, such as beta, delta and lambda.

This was proven by the viral load in the lungs and nose.

Second generation vaccine with optimized mRNA

"The current study shows that the immune responses and the resulting protective effect of our second-generation vaccine candidate, which is based on our mRNA technology after implementation of targeted optimizations, have been significantly improved in non-human primates," explains Dr. Igor Splawski, Chief Scientific Officer at Curevac. As the test series showed, the vaccinated animals were better protected against the coronavirus and against some variants.

"Following the current preclinical development of CV2CoV, a clinical phase 1 study is expected to begin in the fourth quarter of 2021," said Curevac.

It is still a long time before the new generation of the CVnCoV vaccine can be approved.

Meanwhile, the company's share is rising again, but is far behind compared to Biontech and Moderna.

It remains to be seen how the start of the study will affect the stock.

(swa)

List of rubric lists: © STAR-MEDIA via www.imago-images.de

Source: merkur

All news articles on 2021-08-23

You may like

News/Politics 2024-03-16T18:46:42.470Z
News/Politics 2024-03-18T14:18:09.201Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.